Rosemary Mazanet

Colt Ventures Ltd (Colt Ventures) is a venture capital firm founded in 2003 by Darren Blanton. The firm is headquartered in Dallas, Texas.

Argenis Capital Advisors LLC is an independent hedge fund manager headquartered in New York City. Founded in 2006, the firm provides investment advice to high net worth individual and institutional clients.

Apelles Investment Management LP is a hedge fund manager located in New York Cit

Founded in 2004, Diabetes America has established a reputation in communities across Texas as a comprehensive health center and management program for individuals with diabetes, providing them with a team of physicians, dietitians, and certified diabetes educators all under one roof. Diabetes America's personalized education and lifestyle support provide patients with lifelong guidance for managing their diabetes and gives them the tools and support they need to take charge of their lives.

Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA.

Actinium Pharmaceuticals, Inc. provides development and commercialization of alpha particle immunotherapeutics services. It conducts research based on a patient position for the utilization of actinium-225 and bismuth-213. The company has offices in Oak Ridge, TN and Alexandria, VA. Actinium Pharmaceuticals was founded in 1993 and is headquartered in Florham Park, NJ.

Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV.

Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation.